Motus GI to Present at the Oppenheimer & Co. Inc. Fall Healthcare Summit
Motus GI Holdings (NASDAQ: MOTS) announced its management team will present at the Oppenheimer & Co. Inc. Fall Healthcare Summit on September 21, 2021, at 9:55 AM ET. The company, known for its endoscopy solutions aimed at improving gastrointestinal condition management, will also engage in virtual investor meetings from September 20-21, 2021. A replay of the webcast will be available for 90 days on their website. For more information, visit www.motusgi.com.
- None.
- None.
FORT LAUDERDALE, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Summit.
Oppenheimer & Co. Inc. Fall Healthcare Summit
| Presentation Date: | Tuesday, September 21, 2021 at 9:55 AM ET |
| Meetings: | Management is participating in virtual investor meetings on September 20 – 21, 2021 |
| Webcast: | https://wsw.com/webcast/oppenheimer16/mgh/2533460 |
A replay of the webcast will be archived on the Events page on the company’s website, www.moutsgi.com and will be available for 90 days.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the exercise of the warrants, the use of proceeds, the Company’s product development and commercialization, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
FAQ
When is Motus GI's presentation at the Oppenheimer Fall Healthcare Summit?
What is the purpose of the Oppenheimer Fall Healthcare Summit?
How can I access the Motus GI webinar replay?
Will Motus GI have virtual meetings at the summit?
What are the main products offered by Motus GI?
